Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study

BMC Infectious Diseases

Christine U Oramasionwu¹  Lu Mao²  Joshua C Toliver¹  Terence L Johnson¹ 

[1] University of North Carolina, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Chapel Hill, NC 27599-7355, 2215 Kerr Hall, USA;University of North Carolina, UNC Gillings School of Global Public Health and the UNC Center for AIDS Research (CFAR) Biostatistics Core, Chapel Hill, NC, USA

关键词: Utilization;    Therapy;    Antiviral;    Antiretroviral;    Coinfection;    HCV;    HIV;   

Others  :  1134039
DOI  :  10.1186/1471-2334-14-217

 received in 2014-03-19, accepted in 2014-04-09,  发布年份 2014

【 摘 要 】

Background

Few studies have explored how utilization of outpatient services differ for HIV/HCV coinfected patients compared to HIV or HCV monoinfected patients. The objectives of this study were to (1) compare annual outpatient clinic visit rates between coinfected and monoinfected patients, (2) to compare utilization of HIV and HCV therapies between coinfected and monoinfected patients, and (3) to identify factors associated with therapy utilization.

Methods

Data were from the 2005–2010 U.S. National Hospital Ambulatory Medical Care Surveys. Clinic visits with a primary or secondary ICD-9-CM codes for HIV or HCV were included. Coinfection included visits with codes for both HIV and HCV. Monoinfection only included codes for HIV or HCV, exclusively. Patients <15 years of age at time of visit were excluded. Predictors of HIV and HCV therapy were determined by logistic regressions. Visits were computed using survey weights.

Results

3,021 visits (11,352,000 weighted visits) met study criteria for patients with HIV/HCV (8%), HIV (70%), or HCV (22%). The HCV subgroup was older in age and had the highest proportion of females and whites as compared to the HIV/HCV and HIV subgroups. Comorbidities varied significantly across the three subgroups (HIV/HCV, HIV, HCV): current tobacco use (40%, 27%, 30%), depression (32%, 23%, 24%), diabetes (9%, 10%, 17%), and chronic renal failure (<1%, 3%, 5%), (p < 0.001 for all variables). Annual visit rates were highest in those with HIV, followed by HIV/HCV, but consistently lower in those with HCV. HIV therapy utilization increased for both HIV/HCV and HIV subgroups. HCV therapy utilization remained low for both HIV/HCV and HCV subgroups for all years. Coinfection was an independent predictor of HIV therapy, but not of HCV therapy.

Conclusion

There is a critical need for system-level interventions that reduce barriers to outpatient care and improve uptake of HCV therapy for patients with HIV/HCV coinfection.

【 授权许可】

   
2014 Johnson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA: The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011, 18(7):506-512.
• [2]Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335(15):1091-1098.
• [3]McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339(21):1485-1492.
• [4]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351(5):438-450.
• [5]Ananthakrishnan AN, McGinley EL, Fangman J, Saeian K: Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. J Viral Hepat 2010, 17(10):720-729.
• [6]Vellozzi C, Buchacz K, Baker R, Spradling PR, Richardson J, Moorman A, Tedaldi E, Durham M, Ward J, Brooks JT: Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999–2007. J Viral Hepat 2011, 18(5):316-324.
• [7]Agency for Healthcare Research and Quality: 2012 National Healthcare Disparities Report. June 2013. Available at http://www.ahrq.gov/research/findings/nhqrdr/nhdr12/index.html webcite. Accessed March 17, 2014
• [8]McCaig LF, Burt CW: Understanding and interpreting the National Hospital Ambulatory Medical Care Survey: key questions and answers. Ann Emerg Med 2012, 60(6):716-721. e711
• [9]Centers for Medicare & Medicaid Services: Medicaid Eligibility. Available at http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Eligibility/Eligibility.html webcite. Accessed March 5, 2014
• [10]Centers for Medicare & Medicaid Services: Medicare Program: General Information. Available at http://www.cms.gov/Medicare/Medicare-General-Information/MedicareGenInfo/index.html webcite. Accessed March 5, 2014
• [11]Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG: Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract 2013, 67(1):6-13.
• [12]Butt AA, Tsevat J, Leonard AC, Shaikh OS, McMahon D, Khan UA, Dorey-Stein Z, Lo Re V III: Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 2009, 13(4):449-455.
• [13]Chak E, Talal AH, Sherman KE, Schiff ER, Saab S: Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31(8):1090-1101.
• [14]Centers for Disease Control and Prevention: HIV Surveillance Report, 2011; vol. 23. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ webcite Published February 2013. Accessed January 22, 2014
• [15]Centers for Disease Control and Prevention: HIV/AIDS and Viral Hepatitis. http://www.cdc.gov/hepatitis/Populations/hiv.htm webcite. Accessed March 17, 2014
• [16]Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ, Naggie S: Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS 2012, 26(9):541-545.
• [17]Cheung R, Mannalithara A, Singh G: Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US. Dig Dis Sci 2010, 55(6):1744-1751.
• [18]Tsui JI, Maselli J, Gonzales R: Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci 2009, 54(12):2694-2698.
• [19]Chen TY, Ding EL, Seage Iii GR, Kim AY: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49(10):1605-1615.
• [20]Grebely J, Oser M, Taylor LE, Dore GJ: Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013, 207(Suppl 1):S19-S25.
• [21]Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, Moore RD, Thomas DL, Sulkowski MS: Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012, 308(4):370-378.
• [22]Scott JD, Wald A, Kitahata M, Krantz E, Drolette L, Corey L, Wang CC: Hepatitis c virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS 2009, 23(11):925-929.
• [23]Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents: Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medical Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf webcite. Accessed March 12, 2014
• [24]American Association for the Study of Liver Diseases and the Infectious Diseases Society of America: Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/full-report-view webcite. Accessed March 17, 2014
• [25]Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessoa MG, Lin A, Tietz A, Connell EV, Diago M: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010, 139(5):1593-1601.
• [26]Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellon JM, González-García J: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50(2):407-413.
• [27]Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, HALT-C Trial Group: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52(3):833-844.
• [28]Dore GJ: The changing therapeutic landscape for hepatitis C. Med J Aust 2012, 196(10):629-632.
• [29]Taylor LE, Swan T, Mayer KH: HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012, 55(Suppl 1):S33-S42.
• [30]Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf webcite. Accessed March 12, 2014
• [31]Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Skinner J, Frei CR: Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996–2006. South Med J 2011, 104(12):794-800.
• [32]Whiteside YO, Cohen SM, Bradley H, Skarbinski J, Hall HI, Lansky A: Progress along the continuum of HIV care among blacks with diagnosed HIV- United States, 2010. MMWR Morb Mortal Wkly Rep 2014, 63(5):85-89.
• [33]Gaston GB, Alleyne-Green B: The impact of African Americans' beliefs about HIV medical care on treatment adherence: a systematic review and recommendations for interventions. AIDS Behav 2013, 17(1):31-40.
• [34]Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M: Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS 2009, 23(9):715-725.
• [35]U.S. Department of Health and Human Services: Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. Washington, DC: U.S: Department of Health and Human Services; 2011:1-76.